TME Pharma NVXPAR:ALTME -3.45% Piotroski F-Score is 2 as of Jul. 11, 2026, which is 33% below its 10-year median of 3.00. The stock has 4 warning signs investors should review. Among 1,332 Biotechnology companies, TME Pharma NV ranks worse than 72.97% on this metric.
Warning Sign:
Piotroski F-Score of 2 is low, which usually implies poor business operation.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
TME Pharma NV has an F-score of 2. It is a bad or low score, which usually implies poor business operation.
The historical rank and industry rank for TME Pharma NV's Piotroski F-Score or its related term are showing as below:
XPAR:ALTME'
s Piotroski F-Score Range Over the Past 10 Years
Min: 1 Med: 3 Max: 5
Current: 2
During the past 12 years, the highest Piotroski F-Score of TME Pharma NV was 5. The lowest was 1. And the median was 3.
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
TME Pharma NV Piotroski F-Score Related Terms
TME Pharma NV Piotroski F-Score Historical Data
* Premium members only.
The historical data trend for TME Pharma NV's Piotroski F-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XPAR:ALTME vs VRTX, REGN, ALNY: Piotroski F-Score Comparison
For the Biotechnology subindustry, TME Pharma NV's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TME Pharma NV Piotroski F-Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, TME Pharma NV's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where TME Pharma NV's Piotroski F-Score falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
TME Pharma NV's current Net Income (TTM) was -3.29.
==> Negative ==> Score 0.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
TME Pharma NV's return on assets of this year was -0.96447446. TME Pharma NV's return on assets of last year was -2.29706945.
==> This year is higher. ==> Score 1.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
TME Pharma NV's current ratio of this year was 0.57073696. TME Pharma NV's current ratio of last year was 1.87667411.
==> Last year's current ratio is higher ==> Score 0.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
TME Pharma NV's number of shares in issue this year was 94.151. TME Pharma NV's number of shares in issue last year was 35.981.
==> There is larger number of shares in issue this year. ==> Score 0.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
TME Pharma NV's gross margin of this year was . TME Pharma NV's gross margin of last year was .
==> Last year's gross margin is higher ==> Score 0.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
TME Pharma NV's asset turnover of this year was 0. TME Pharma NV's asset turnover of last year was 0.
==> Last year's asset turnover is higher ==> Score 0.
Evaluation
Piotroski F-Score
=
Que. 1
+
Que. 2
+
Que. 3
+
Que. 4
+
Que. 5
+
Que. 6
+
Que. 7
+
Que. 8
+
Que. 9
=
0
+
0
+
1
+
0
+
1
+
0
+
0
+
0
+
0
=
2
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
TME Pharma NV has an F-score of 2. It is a bad or low score, which usually implies poor business operation.
TME Pharma NV (XPAR:ALTME) has a Piotroski F-Score of 2 as of Jul. 11, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on TME Pharma NV and its competitors. This is 33% below median its historical median of 3.00. Over the past decade, TME Pharma NV's Piotroski F-Score has ranged from 1.00 to 5.00. According to the industry distribution chart, TME Pharma NV ranks #972 out of 1332 companies in the Biotechnology industry, placing it in the top 73%.
Is TME Pharma NV's Piotroski F-Score too high?
TME Pharma NV's current Piotroski F-Score of 2 is 33% below median its 10-year median of 3.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 5.00. The Biotechnology industry median Piotroski F-Score is 3.00. TME Pharma NV's value of 2 is 33.3% below this industry median. Based on the distribution chart, TME Pharma NV ranks #972 out of 1332 companies in the Biotechnology industry, which is below the industry midpoint.
How does TME Pharma NV's Piotroski F-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, TME Pharma NV ranks #972 out of 1332 companies for Piotroski F-Score. This places TME Pharma NV in the lower half of its industry. The industry median Piotroski F-Score is 3.00. TME Pharma NV's value of 2 is 33.3% below this benchmark. Historically, TME Pharma NV's own Piotroski F-Score has ranged from 1.00 to 5.00 over the past decade. While the company's 10-year median is 3.00 vs. the industry median of 3.00, TME Pharma NV has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Biotechnology company?
The median Piotroski F-Score among Biotechnology companies is 3.00, based on 1,332 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TME Pharma NV's current Piotroski F-Score of 2 is 33.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on TME Pharma NV and its competitors. For the Biotechnology industry, the median Piotroski F-Score is 3.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TME Pharma NV's current Piotroski F-Score is 2, which is 33% below median its own 10-year median of 3.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TME Pharma NV stock overvalued right now?
TME Pharma NV (XPAR:ALTME) has a current Piotroski F-Score of 2. The current Piotroski F-Score is 2, which is 33% below median its 10-year median of 3.00 and 33.3% below the Biotechnology industry median of 3.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For TME Pharma NV (XPAR:ALTME), the current Piotroski F-Score is 2 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
TME Pharma NV is a clinical-stage biopharmaceutical company focused on developing novel therapies for treatment of the aggressive cancers and specializing in approaches targeting the tumor microenvironment. Its enhances the effectiveness of cancer treatments including current standards of care (such as antivascular agents, chemotherapy and radiotherapy) and immune-oncology approaches (such as immune checkpoint inhibitors). The company's Spiegelmer platform has generated a proprietary pipeline of clinical-stage product candidates including its cancer drug candidate NOX-A12 and its second clinical-stage asset, NOX-E36, now planned to be developed in eye diseases. The company has one segment active in pioneering the development of a new class of proprietary therapeutics called Spiegelmers.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAR:ALTME has been successfully added to your 